Drug profile · INN
netarsudil
RHOKIINSA
netarsudil (RHOKIINSA) is a rho-associated protein kinase inhibitor. Route of administration: drops. Current US regulatory status: approved.
Drug details — netarsudil
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- DROPS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
netarsudil (RHOKIINSA) is a rho-associated protein kinase inhibitor. Route of administration: drops. Current US regulatory status: approved.
Key facts
Mechanism of action
Rho-associated protein kinase inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is netarsudil?
netarsudil (RHOKIINSA) is a rho-associated protein kinase inhibitor. Route of administration: drops. Current US regulatory status: approved.
What is the brand name for netarsudil?
RHOKIINSA is a marketed brand name for netarsudil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of netarsudil?
netarsudil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.